| Source: |
Escherichia coli. |
| Molecular Weight: |
Approximately 19.7 kDa, a single non-glycosylated polypeptide chain containing 173 amino acids. |
| AA Sequence: |
ETFPPKYLHY DEETSHQLLC DKCPPGTYLK QHCTAKWKTV CAPCPDHYYT DSWHTSDECL YCSPVCKELQ YVKQECNRTH NRVCECKEGR YLEIEFCLKH RSCPPGFGVV QAGTPERNTV CKRCPDGFFS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK |
| Purity: |
> 95% by SDS-PAGE and HPLC analyses. |
| Biological Activity: |
Fully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/mL, corresponding to a specific activity of > 1.0 × 105 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL). |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB,150 mM NaCl, pH6.0. |
| Endotoxin: |
Less than 1 EU/μg of rHuOPG as determined by LAL method. |
| Reconstitution: |
Centrifuge the vial briefly before opening to ensure that the contents settle at the bottom. Reconstitute the vial with sterile distilled water or an aqueous buffer containing 0.1% BSA to achieve a concentration of 0.1-1.0 mg/mL. Divide the resulting stock solution into working aliquots and store them at or below -20°C. For further dilutions, use appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Synonyms: |
TNFRSF11B, Osteoclastogenesis Inhibitory Factor, Tumor Necrosis Factor Receptor Superfamily Member 11B |
| Background: |
Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor (OCIF) and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a protein encoded by the TNFRSF11B gene in humans. This basic glycoprotein is 401 amino acids long and consists of seven structural domains. It exists either as a 60 kDa monomer or a 120 kDa dimer connected by disulfide bridges. OPG serves as a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL), inhibiting osteoclast activation and promoting their apoptosis in vitro. It may also help prevent arterial calcification. OPG has been used to reduce bone resorption in postmenopausal women with osteoporosis and in patients with bone metastases that cause tissue destruction. Mature human OPG shares a high degree of amino acid sequence identity with its counterparts in other species, including 86% with mouse, 87% with rat, 92% with equine and canine, and 88% with bovine OPG. |
